1-(1-甲基-4-苯基哌啶-4-基)丙烷-1-酮 | 7475-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(1-甲基-4-苯基哌啶-4-基)丙烷-1-酮
• 英文名称: 1-(1-methyl-4-phenylpiperidin-4-yl)propan-1-one
• 英文别名: meperidine；1-(1-methyl-4-phenyl-[4]piperidyl)-propan-1-one；1-(1-Methyl-4-phenyl-[4]piperidyl)-propan-1-on；1-(1-Methyl-4-phenyl-4-piperidinyl)-1-propanone
• CAS: 7475-63-0
• 化学式: C₁₅H₂₁NO
• 分子量: 231.338
• InChiKey: MZCGFXHPRWDPSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-甲基-4-苯基哌啶-4-基)丙烷-1-酮 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1-(1-methyl-4-phenyl-[4]piperidyl)-propan-1-ol
  参考文献：
  名称：

  302.合成止痛药。第五部分与哌替啶有关的化合物

  摘要：

  DOI：

  10.1039/jr9500001467
• 作为产物：
  描述：

  N-甲基二乙醇胺 在 sodium hydroxide 、 氯化亚砜 、 十六烷基三丁基溴化磷 作用下， 以 氯仿 为溶剂， 反应 2.0h， 生成 1-(1-甲基-4-苯基哌啶-4-基)丙烷-1-酮
  参考文献：
  名称：

  凯托米酮前体的合成通过相转移催化

  摘要：

  的盐酸盐ñ -取代的双- （2-氯乙基）胺可以与缩合米甲氧基苯基-乙腈或1-苯基-2-烷酮相转移条件下，以产生强大的镇痛化合物的前体-的ketobemidones。

  DOI：

  10.1002/jhet.5570230115

文献信息

• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders
  申请人：Yamashita Hiroshi

  公开号：US20090264404A1

  公开（公告）日：2009-10-22

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，其化学式为（1）：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香族基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的谱，包括中枢神经系统障碍，无副作用且安全性高。
• DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS
  申请人：YAMASHITA Hiroshi

  公开号：US20120028920A1

  公开（公告）日：2012-02-02

  A heterocyclic compound or a salt thereof represented by the formula (1): where R 2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R 1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种由式（1）所表示的杂环化合物或其盐：其中R2代表氢原子或较低的烷基基团；A代表较低的烷基烯基基团；R1代表芳香基团或杂环基团。本发明的化合物具有广泛的治疗精神障碍的光谱，包括中枢神经系统障碍，无副作用且安全性高。
• Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders
  申请人：Otsuka Pharmaceutical Co., Limited

  公开号：EP2284169A1

  公开（公告）日：2011-02-16

  A heterocyclic compound or a salt thereof represented by the formula (I): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a lower alkenylene group; and R1 represents a benzene fused heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

  一种杂环化合物或其盐，由式（I）代表： 其中 R2 代表氢原子或低级烷基；A 代表低级亚烷基或低级亚烯基；R1 代表苯融合杂环基团。本发明的化合物对包括中枢神经系统疾病在内的精神疾病具有治疗范围广、无副作用、安全性高等特点。
• Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs
  作者：Susan L. Mercer、Christopher W. Cunningham、Natalie D. Eddington、Andrew Coop

  DOI：10.1016/j.bmcl.2008.04.046

  日期：2008.6

  Numerous studies have shown that many clinically employed opioid analgesics are substrates for P-glycoprotein (P-gp), suggesting that up-regulation of P-gp may contribute to the development of central tolerance to opioids. The studies herein focus on the development of SAR for P-gp substrate activity in the meperidine series of opioids. Addition of a 3-OH to meperidine and the ketone analog of meperidine yielding bemidone and ketobemidone, respectively, significantly increased P-gp substrate affinity. The results of this study have implications in the development of novel analgesics to be utilized as tools to study the contribution of P-gp on the development of central tolerance to opioids. (C) 2008 Elsevier Ltd. All rights reserved.
• US2546159
  申请人：——

  公开号：——

  公开（公告）日：——